Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Myeloid 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Hematologic Diseases 1Bone Marrow Neoplasms 1Bone Marrow Diseases 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × SCIO-469 × Clear all
NCT00113893 2013-11-07

SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes.

Scios, Inc.

Phase 2 Completed
62 enrolled
Myeloid

Bone Marrow Diseases, Hematologic Diseases, Myelodysplastic Syndromes, Bone Marrow Neoplasms

NCT00095680 2010-10-22

Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

Scios, Inc.

Phase 2 Completed
30 enrolled
Plasma cell

Multiple Myeloma

NCT00087867 2010-10-18

Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

Scios, Inc.

Phase 2 Completed
62 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡